Likewise, CSF levels of phosphorylated tau (p-tau) and total tau (t-tau), biomarkers of tau pathology and neurodegeneration or injury, respectively, have been used successfully together or in combination with Aβ42 as positive indicators of existing AD pathology [18, 25]. The gene discussed is MAPT; the disease is Alzheimer disease.